Brokerages expect Nu Skin Enterprises, Inc. (NYSE:NUS) to post earnings per share (EPS) of $0.72 for the current quarter, Zacks reports. Three analysts have provided estimates for Nu Skin Enterprises’ earnings. The lowest EPS estimate is $0.71 and the highest is $0.73. Nu Skin Enterprises reported earnings of $1.05 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 31.4%. The business is expected to report its next earnings results after the market closes on Wednesday, February 12th.
On average, analysts expect that Nu Skin Enterprises will report full-year earnings of $3.11 per share for the current financial year, with EPS estimates ranging from $3.10 to $3.12. For the next year, analysts anticipate that the business will report earnings of $3.29 per share, with EPS estimates ranging from $3.18 to $3.37. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Nu Skin Enterprises.
Nu Skin Enterprises (NYSE:NUS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.76 by $0.03. The business had revenue of $590.00 million during the quarter, compared to the consensus estimate of $605.02 million. Nu Skin Enterprises had a return on equity of 23.52% and a net margin of 4.59%. The business’s revenue for the quarter was down 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.94 earnings per share.
A number of equities research analysts have issued reports on the company. ValuEngine raised Nu Skin Enterprises from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Stifel Nicolaus raised Nu Skin Enterprises from a “sell” rating to a “hold” rating and boosted their price target for the company from $38.50 to $45.00 in a research report on Tuesday, October 29th. Zacks Investment Research cut Nu Skin Enterprises from a “hold” rating to a “sell” rating and set a $44.00 price objective on the stock. in a research note on Monday, November 11th. Citigroup restated a “neutral” rating and set a $43.00 price objective on shares of Nu Skin Enterprises in a research note on Thursday, December 5th. Finally, DA Davidson set a $42.00 price objective on Nu Skin Enterprises and gave the stock a “hold” rating in a research note on Friday, October 11th. Two analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $49.50.
NUS stock opened at $40.79 on Thursday. The stock has a 50-day moving average price of $39.40 and a two-hundred day moving average price of $41.66. Nu Skin Enterprises has a 12-month low of $35.03 and a 12-month high of $69.79. The company has a current ratio of 2.01, a quick ratio of 1.24 and a debt-to-equity ratio of 0.50. The company has a market cap of $2.27 billion, a PE ratio of 11.87, a price-to-earnings-growth ratio of 1.34 and a beta of 0.77.
In other news, insider Foulis Greg 500,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. Corporate insiders own 3.20% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its holdings in shares of Nu Skin Enterprises by 3.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 562,247 shares of the company’s stock valued at $27,731,000 after purchasing an additional 18,544 shares during the last quarter. Voloridge Investment Management LLC grew its holdings in shares of Nu Skin Enterprises by 499.4% during the third quarter. Voloridge Investment Management LLC now owns 38,755 shares of the company’s stock valued at $1,648,000 after purchasing an additional 32,289 shares during the last quarter. First Trust Advisors LP grew its holdings in shares of Nu Skin Enterprises by 3.1% during the third quarter. First Trust Advisors LP now owns 236,053 shares of the company’s stock valued at $10,039,000 after purchasing an additional 7,089 shares during the last quarter. California Public Employees Retirement System grew its holdings in shares of Nu Skin Enterprises by 38.3% during the third quarter. California Public Employees Retirement System now owns 104,674 shares of the company’s stock valued at $4,452,000 after purchasing an additional 28,996 shares during the last quarter. Finally, 1492 Capital Management LLC bought a new position in shares of Nu Skin Enterprises during the third quarter valued at approximately $1,373,000. Hedge funds and other institutional investors own 72.47% of the company’s stock.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products.
Featured Article: Bid-Ask Spread
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.